161 related articles for article (PubMed ID: 25812850)
21. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.
Schoonenboom NS; Reesink FE; Verwey NA; Kester MI; Teunissen CE; van de Ven PM; Pijnenburg YA; Blankenstein MA; Rozemuller AJ; Scheltens P; van der Flier WM
Neurology; 2012 Jan; 78(1):47-54. PubMed ID: 22170879
[TBL] [Abstract][Full Text] [Related]
22. Total glutamine synthetase levels in cerebrospinal fluid of Alzheimer's disease patients are unchanged.
Timmer NM; Herbert MK; Claassen JA; Kuiperij HB; Verbeek MM
Neurobiol Aging; 2015 Mar; 36(3):1271-3. PubMed ID: 25577411
[TBL] [Abstract][Full Text] [Related]
23. Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-β42 levels in Lewy body disease.
Maetzler W; Stoycheva V; Schmid B; Schulte C; Hauser AK; Brockmann K; Melms A; Gasser T; Berg D
J Alzheimers Dis; 2010; 22(3):933-8. PubMed ID: 20858953
[TBL] [Abstract][Full Text] [Related]
24. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
[TBL] [Abstract][Full Text] [Related]
25. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
[TBL] [Abstract][Full Text] [Related]
26. Neuropsychological and behavioural correlates of CSF biomarkers in dementia.
Engelborghs S; Maertens K; Vloeberghs E; Aerts T; Somers N; Mariën P; De Deyn PP
Neurochem Int; 2006 Mar; 48(4):286-95. PubMed ID: 16434124
[TBL] [Abstract][Full Text] [Related]
27. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
Aerts MB; Esselink RA; Claassen JA; Abdo WF; Bloem BR; Verbeek MM
J Alzheimers Dis; 2011; 27(2):377-84. PubMed ID: 21841257
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders.
Nutu M; Zetterberg H; Londos E; Minthon L; Nägga K; Blennow K; Hansson O; Ohrfelt A
Dement Geriatr Cogn Disord; 2013; 36(1-2):99-110. PubMed ID: 23860354
[TBL] [Abstract][Full Text] [Related]
29. Cerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal Dementia.
Rostgaard N; Waldemar G; Nielsen JE; Simonsen AH
Dement Geriatr Cogn Disord; 2015; 40(1-2):54-62. PubMed ID: 25998699
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid levels of a 20-22 kDa NH2 fragment of human tau provide a novel neuronal injury biomarker in Alzheimer's disease and other dementias.
Amadoro G; Corsetti V; Sancesario GM; Lubrano A; Melchiorri G; Bernardini S; Calissano P; Sancesario G
J Alzheimers Dis; 2014; 42(1):211-26. PubMed ID: 24851856
[TBL] [Abstract][Full Text] [Related]
31. CSF neurofilament proteins in the differential diagnosis of dementia.
de Jong D; Jansen RW; Pijnenburg YA; van Geel WJ; Borm GF; Kremer HP; Verbeek MM
J Neurol Neurosurg Psychiatry; 2007 Sep; 78(9):936-8. PubMed ID: 17314187
[TBL] [Abstract][Full Text] [Related]
32. Altered CSF orexin and α-synuclein levels in dementia patients.
Wennström M; Londos E; Minthon L; Nielsen HM
J Alzheimers Dis; 2012; 29(1):125-32. PubMed ID: 22207004
[TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T
Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286
[TBL] [Abstract][Full Text] [Related]
34. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
[TBL] [Abstract][Full Text] [Related]
35. Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels.
Slaets S; Vanmechelen E; Le Bastard N; Decraemer H; Vandijck M; Martin JJ; De Deyn PP; Engelborghs S
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S290-8. PubMed ID: 24439167
[TBL] [Abstract][Full Text] [Related]
36. Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies.
Slaets S; Le Bastard N; Theuns J; Sleegers K; Verstraeten A; De Leenheir E; Luyckx J; Martin JJ; Van Broeckhoven C; Engelborghs S
J Alzheimers Dis; 2013; 35(1):137-46. PubMed ID: 23364139
[TBL] [Abstract][Full Text] [Related]
37. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
Kaerst L; Kuhlmann A; Wedekind D; Stoeck K; Lange P; Zerr I
J Alzheimers Dis; 2014; 38(1):63-73. PubMed ID: 23948928
[TBL] [Abstract][Full Text] [Related]
38. Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders.
Spies PE; Melis RJ; Sjögren MJ; Rikkert MG; Verbeek MM
J Alzheimers Dis; 2009; 16(2):363-9. PubMed ID: 19221426
[TBL] [Abstract][Full Text] [Related]
39. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease.
Mollenhauer B; Bibl M; Trenkwalder C; Stiens G; Cepek L; Steinacker P; Ciesielczyk B; Neubert K; Wiltfang J; Kretzschmar HA; Poser S; Otto M
J Neural Transm (Vienna); 2005 Jul; 112(7):933-48. PubMed ID: 15937638
[TBL] [Abstract][Full Text] [Related]
40. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
Engelborghs S
Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
